Short interfering RNAs targeted to T-LAK cell-originated protein kinase (TOPK) polynucleotide
AssigneeOncotherapy Science, Inc.
InventorsYusuke Nakamura, Toyomasa Katagiri, Shuichi Nakatsuru
Life of this patent
Estimating the term…
Loading patent…
AssigneeOncotherapy Science, Inc.
InventorsYusuke Nakamura, Toyomasa Katagiri, Shuichi Nakatsuru
Estimating the term…
Objective methods for detecting and diagnosing breast cancer (BRC) are described herein. In one embodiment, the diagnostic method involves determining the expression level of a BRC-associated gene that discriminates between BRC cells and normal cells. In another embodiment, the diagnostic method involves determining the expression level of a BRC-associated gene that discriminates among BRC cells, between DCIS and IDC cells. The present invention further provides means for predicting and preventing breast cancer metastasis using BRC-associated genes having unique altered expression patterns in breast cancer cells with lymph-node metastasis. Finally, the present invention provides methods of screening for therapeutic agents useful in the treatment of breast cancer, methods of treating breast cancer and method for vaccinating a subject against breast cancer.
A composition for treating or preventing breast cancer, said composition comprising a pharmaceutically effective amount of an siRNA against a T-LAK cell-originated protein kinase (TOPK) polynucleotide, wherein the target sequence of said siRNA comprises the sense strand comprising a nucleotide sequence selected from the group consisting of nucleotide sequences of SEQ ID NO:
Dependencies are inferred from the claim text.